Navigation Links
Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be Held on February 15, 2012
Date:2/15/2012

CRANBURY, N.J., Feb. 15, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its second quarter ended December 31, 2011.  Palatin reported a net loss of $2.6 million, or $(0.08) per basic and diluted share, for the quarter ended December 31, 2011, compared to a net loss of $1.1 million, or $(0.09) per basic and diluted share, for the same period in 2010.  

The increase in net loss for the quarter ended December 31, 2011, compared to the same period last fiscal year, is attributable to costs related to Palatin's ongoing Phase 2B clinical trial with bremelanotide for Female Sexual Dysfunction (FSD) and a decrease in grant and contract revenue.

REVENUERevenues for the quarter ended December 31, 2011 were $11,492, which consisted of contract revenue pursuant to its collaboration agreement with AstraZeneca. For the quarter ended December 31, 2010, Palatin recognized revenue of $1.0 million, consisting of $846,768 in grant revenue received under the Patient Protection and Affordable Care Act of 2010 and $195,408 in contract revenue under its collaboration agreement with AstraZeneca.

COSTS AND EXPENSESTotal operating expenses for the quarter ended December 31, 2011 were $3.7 million compared to $2.9 million for the comparable quarter of 2010.  The increase in operating expenses for the quarter was primarily due to costs related to Palatin's ongoing Phase 2B clinical trial with bremelanotide for FSD.

CASH POSITION Palatin's cash and cash equivalents as of December 31, 2011 were $11.9 million, with $1.1 million in accounts receivable due from the sale of Palatin's New Jersey state net operating loss carryforwards, and curre
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Palatin Technologies Receives $1.1 Million From Sale of New Jersey State Tax Credits
2. Palatin Technologies to Present at BOCEMb, Noble Financial Capital Markets Eighth Annual Equity Conference
3. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
4. Alan Dunton, M.D., Joins Board of Directors of Palatin Technologies, Inc.
5. Palatin Technologies, Inc. March 31, 2011 Quarter Results; Teleconference and Webcast to be Held on May 16, 2011
6. FDA Clears Palatin Technologies IND Filing to Commence Clinical Studies for Asthma
7. Palatin Technologies, Inc. Closes $23 Million Public Offering
8. Palatin Technologies Listing Compliance Plan Accepted by NYSE Amex
9. Palatin Technologies Receives Non-Compliance Letter from NYSE Amex
10. Palatin Technologies to Present at 9th Annual BIO Investor Forum
11. Palatin Technologies to Present at Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Tenn. , Sept. 16, 2014 A ... investigators has found the chemotherapy dose threshold below ... normal sperm production. The study appears in September 17 ... By clarifying which patients are at highest risk ... findings to eventually increase use of pre-treatment fertility preservation ...
(Date:9/16/2014)... -- Chindex International, Inc. ("Chindex" or the "Company") (Nasdaq: ... meeting of stockholders held today, the Company,s stockholders adopted ... and among the Company, Healthy Harmony Holdings, L.P. ("Parent"), ... an affiliate of TPG, Shanghai Fosun Pharmaceutical (Group) Co., ... CEO of the Company. The Merger Agreement ...
(Date:9/16/2014)... , Sept. 16, 2014 Research and Markets ... Vaccines Market 2014-2018" report to their offering. ... immunity of animals. Animal vaccines are generally prepared from weakened ... in their healthy state. Some of the animal vaccines are ... as protein subunits or toxic components. These ...
Breaking Medicine Technology:Improved risk identification will aid fertility preservation in young male cancer patients 2Improved risk identification will aid fertility preservation in young male cancer patients 3Improved risk identification will aid fertility preservation in young male cancer patients 4Chindex Stockholders Approve Merger 2Chindex Stockholders Approve Merger 3Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 2Global Animal Vaccines Market 2014-2018: Key Vendors are Bayer, Elanco, Merck, Novartis, Sanofi and Zoetis 3
... BioStorage Technologies, Inc., a worldwide provider of long- and ... logistics, will expand its European operations with the opening ... full-service biorepository in Frankfurt, Germany. , BioStorage Technologies, expanded ... plan to accommodate a rapidly growing list of customers ...
... Oct. 21 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHMD) ... bavituximab in combination with docetaxel in patients with advanced breast ... planned treatment cycles in the Phase II study showed that ... the trial achieved an objective tumor response according to RECIST ...
Cached Medicine Technology:BioStorage Technologies, Inc., Accelerates European Expansion with Opening of New German Facility 2Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer 2Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer 3Peregrine Pharmaceuticals Reports 61% Objective Response Rate in 46-Patient Bavituximab Phase II Trial in Advanced Breast Cancer 4
(Date:9/17/2014)... 17, 2014 ICS Learning Group, Inc. ... Excellence in Training for the Best Use of Games ... on an online operational safety training module that ICS ... operation. Using an approach that combined realistic 3D ... that was similar to a video game, including competition ...
(Date:9/17/2014)... 2014 Health.Verticalize, a healthcare marketing company ... health insurance options in the 2014 open enrollment period, ... Moving forward Health Network will be using ... has intentionally remained out of the spotlight for the ... single website to its present position with dozens of ...
(Date:9/16/2014)... Recently, BamboofloorChina.com, the popular online supplier ... of strand woven bamboo floors to its ... big promotion for the new items; the current discount ... is a great shopping season. Therefore, BamboofloorChina.com spares no ... new customers. All practical items offered by BamboofloorChina.com are ...
(Date:9/16/2014)... UK report a poorer experience of care during pregnancy ... their care, suggests a new study published today (17 ... and Gynaecology ( BJOG ). , Differences in ... in many areas and have provided the focus for ... inequalities. , The Oxford University study, funded by the ...
(Date:9/16/2014)... Holganix, an elite member of the Inc ... the country, produces an organic Bionutritional product that promotes ... decreasing disease and insect damage though significant root and ... hold its third annual Bionutritional Summit at the Seelbach ... 1:00 P.M. through 6:00 P.M., the day before the ...
Breaking Medicine News(10 mins):Health News:ICS Learning Group Wins Gold in the 2014 Brandon Hall Excellence Competition for Best Use of Games and Simulations for Learning 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 2Health News:Health.Verticalize Rebrands as Health Network After Growing to 15 Million Users in Less Than One Year 3Health News:BamboofloorChina.com Announces Its Promotion For Strand Woven Bamboo Floors 2Health News:A greater focus on socially disadvantaged women is needed to improve maternity care in England 2Health News:Holganix Holds 3rd Annual Bionutrional Summit in Louisville, Kentucky 2
... Medical School in the South West of England have ... out of hours services in primary care are reluctant ... and carried out telephone interviews with 27 patients who ... practice cover in the evenings and weekends in England. ...
... WANTAGH, N.Y., Nov. 29 As family members age, ... performing daily,tasks, such as cooking and laundry. Some need ... professional medical care, and most,want to stay in the ... how to keep their parents safe, healthy and cared ...
... U.S. is caused by a form of bacteria, the ... It typically begins with a bulls-eye skin rash, accompanied ... If diagnosed early, Lyme can be treated successfully within ... Nearly 60 percent of patients who do not receive ...
... Appointed Worldwide Managing Partners, NEW YORK, Nov. ... the,largest fully integrated, global health marketing and communications ... the credit going to,its unique leadership team whose ... leadership, effective immediately, Doug Burcin and Donna,Murphy, Partners, ...
... -- There are estimated to be ... diagnosed with chronic Immune Thrombocytopenic Purpura (ITP), an ... platelets in their blood -- causing bruises, nosebleeds ... of an international multicenter clinical research study led ...
... Receives Failing Grades on Key Benchmarks, WASHINGTON, ... its first-ever state-specific Report,Card on Lung Cancer. The ... lethal disease by the state of Massachusetts. LCA-MA ... Lung cancer is the number one cause of ...
Cached Medicine News:Health News:Out of hours doctors reluctant to do home visits, say patients 2Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 2Health News:Finding Ways for Seniors to Stay Safe, Healthy... and Home 3Health News:Antibody responses in patients with Lyme arthritis 2Health News:Antibody responses in patients with Lyme arthritis 3Health News:World's Largest Fully Integrated, Global Health Marketing and Communications Group Appoints Global Leadership Team 2Health News:World's Largest Fully Integrated, Global Health Marketing and Communications Group Appoints Global Leadership Team 3Health News:Eltrombopag studied in Idiopathic Thrombocytopenic Purpura 2Health News:Lung Cancer Alliance-Massachusetts Issues Inaugural State-Specific Report Card on Lung Cancer 2
... The Accutest H. pylori WB ... for the qualitative detection of ... pylori in human whole blood. ... as an aid in the ...
... Rapid 5 minutes immunoassay, based on ... a monoclonal antibody, for the qualitative ... human stool. The Premier Platinum HpSA, ... after extensive evaluation, was accepted as ...
Unitary one step immuno-chromatographic assay for the qualitative detection of infectious mononucleosis heterophile antibodies in human serum, plasma or whole blood....
The NOW® Flu B test is the most frequently adopted rapid flu test on the market today. Testing could not be easier and the results are available in 15 minutes. Now you can focus on the results an...
Medicine Products: